Q85 – 91: Post-Infusion Treatment Given to Prevent Relapse or Progression

!Malignant Diseases Only
Only complete the Post-Infusion Treatment Given to Prevent Relapse or Progression if the infusion being reported was given to treat a malignant disease. If the infusion being reported was given to treat a non-malignant disease, leave the Post-Infusion Treatment Given to Prevent Relapse or Progression questions blank. FormsNet3^SM should enable / disable this section based on the primary disease reported on the Pre-TED Disease Classification Form (2402) Form. Contact the CIBMTR Customer Service Center if it is believed FormsNet3^SM is incorrectly enabling / disabling these fields.

!Prior Relapse / Progression
If the recipient has had a prior relapse or progression that was reported in a previous reporting period, any therapy given to prevent further relapse / progression (such as maintenance therapy) does not need to be captured and this section of the form is skipped. If the relapse / progression occurred in the current reporting period for which the form is being completed, then this section of the form will need to be completed and will be skipped in subsequent reporting periods.

*Combined Follow-Up
In scenarios where a cell therapy was given after an HCT and this form is now being completed based on the subsequent cell therapy date, these questions do not apply and are disabled. This information will be captured on the corresponding disease-specific form, if applicable.

Report therapy given to prevent relapse or progressive disease, which includes maintenance therapy. Any therapy given for decreased / loss of chimerism, persistent disease, progressive / relapsed disease or MRD consolidation therapy should not be reported in this section and is reported above in the Post-Infusion Intervention for Disease section.

Question 85: Was therapy given to prevent relapse or progressive disease? (Include any maintenance therapy)

Indicate whether therapy was given to prevent relapse or progressive disease (i.e., maintenance) during the reporting period; this therapy may have been specifically planned as part of the original transplant protocol or determined after transplant. Do not include therapy given for decreased / loss of chimerism, persistent disease, progressive / relapsed disease or MRD consolidation therapy. Any post-infusion therapy included as part of the initial transplant protocol should be reported in this area of the form.

Question 86: Specify therapy (check all that apply)

Indicate which therapies were given to prevent relapse or progressive disease in the current reporting period.

• Blinded randomized trial: A blinded, randomized trial refers to a research treatment protocol in which the participant is assigned to the control arm or investigational group, and the researcher or clinician is not informed whether the subject is receiving the placebo or standard of care versus the investigational therapy. This makes it impossible to report agents or therapies the recipient is receiving.
• Intrathecal therapy: Intrathecal therapy is chemotherapy administered to the CNS via a lumbar puncture. It may be given to treat or prevent leukemic blasts in the cerebrospinal fluid or other CNS tissues.
• Radiation: Radiation therapy uses high-energy radiation to kill cancer cells. External beam radiation is one of the more frequently used types of radiation. In this method, a beam of radiation is delivered to a specific part of the body, such as the mediastinum. Radiation may be planned if bulky disease was present just prior to transplant for a recipient with lymphoma or a solid tumor.
• Systemic therapy: refers to a delivery mechanism where a therapeutic agent is delivered orally or intravenously, enters the bloodstream, and is distributed throughout the body.
• Other therapy: Indicate whether the recipient received additional therapy for reasons other than decreased / loss of chimerism, minimal residual disease, persistent disease, or progressive / relapsed disease which does not fit into the previous categories. Examples may include surgery. Do not report a subsequent infusion (i.e. DLI, cellular therapy, subsequent HCT) in this field if one was given. All subsequent infusions will be captured at the top of this form and do not need to be re-reported.
  

!Steroids Administered Post-Infusion
Previously, steroids given for relapsed, persistent, or progressive disease were reported as Other systemic therapy. Steroids (e.g. dexamethasone) are no longer captured on the Post-TED (2450) Form and they should not be reported.

Questions 87 – 89: Specify systemic therapy (check all that apply)

Systemic therapy agents and treatment regimens vary based on disease, prognosis, and protocol. Treatment may consistent of one or multiple drugs and may be given in an inpatient or outpatient setting; additionally, drugs may be administered on a single day, over consecutive days, or continuously.

Indicate which systemic therapy agents were administered during the current reporting period for reasons other than relapse, persistent, or progressive disease. If the recipient received a therapeutic agent that is not listed, select Other systemic therapy and specify the therapy.

Questions 90 – 91: Was the initial therapy date previously reported?

Indicate if the initial therapy given for reasons other than decrease / loss of chimerism, consolidation therapy, MRD, relapse, persistent, or progressive disease was reported in a previous reporting period. The intent of this question is to capture the start date of the first maintenance therapy administered. If the initial start date was not reported in a prior reporting period, select No and report the initial therapy start date.

If maintenance therapy was started, stopped, and restarted, report the date when the therapy first began. If a maintenance therapy was started and then switched to a different maintenance therapy, report the start date of the first maintenance therapy.

If exact date is not known, refer to General Instructions, General Guidelines for Completing Forms for information about reporting partial or unknown dates.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.